Buffeted by lower sales of its Leksell gamma knife and poor currency exchange rates in emerging markets, radiation oncology firm Elekta turned in mixed third-quarter results.
The company reported strong order bookings, but earnings before the deduction of interest, tax and amortization expenses (EBITA) were well below expectations. EBITA for the third quarter of the 2013/2014 fiscal year came in at 37.9 million euros (340 Swedish kronor, SEK) compared with 50.6 million euros (454 SEK) for the same quarter last year, Elekta said.
At the same time, new order bookings came in at 359.1 million euros (SEK 3.224 billion) compared with 318.1 million euros (2.856 billion SEK) in the year-ago quarter, an increase of 15%, the company said.
Net sales amounted to 265.7 million euros (2,385 million SEK) compared with 270.5 million euros (2,428 million SEK) in last year's Q3.
Elekta said it has revised its fiscal 2014 forecast downward, citing lower-than-expected delivery volumes of Leksell Gamma Knife and delays in expected deliveries to emerging markets.
